MCK

Congressional Trades

by 13 members

Ticker disclosure brief

Congressional disclosure records for MCK

A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.

Latest receipt

Rick Larsen

BUY · 2026-07-08

Largest range

$15K – $50K

Ro Khanna

Longest observed gap

175d

Jonathan Jackson

Highest 30d vs SPY

41.3%

Ro Khanna

Purchase rows

52%

Sale rows

46%

Disclosed midpoint

$972K

range estimate

Unique Traders

members

Disclosure timing method

Observed filing gaps are not notice-date findings

The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.

Open >45-day tracker Official rule ↗

Party Breakdown

Democrats86 · 89%

Republicans11 · 11%

Federal awards

all →

2026-07-11$150K
Department of Justice
FY26 B1 MCKESSON CONTRACT MEDS JUL 26
2026-07-09$275K
Department of Justice
FY26 B1 MCKESSON B12648613F MEDS AUG 26
2026-07-09$65K
Department of Justice
FY26 B1 MCKESSON NON-CONT/CONT. JULY 2026
2026-07-09$35K
Department of Justice
ESTIMATE FOR MEDICATIONS NEEDED FOR FOURTH QUARTER 2026.
2026-07-09$31K
Department of Justice
FY26 B1 MCKESSON MEDICATION MAT QTR 4 MAT MEDICATION
2026-07-09$14K
Department of Justice
MCKESSON DRUGS MEDICATIONS CONTRACT # 36W79720D0001 CURRENT PERFORMANCE PERIOD 8-10-24 TO 8-9-26 ALL TERMS AND CONDITIONS REMAIN THE SAME UNDER PARENT CONTRACT SAM VERIFIED
2026-07-09$9K
Department of Justice
FY26 B1 FSA MCKESSON MAT MEDICATION JUL 26
2026-07-09$6K
Department of Justice
RP# 26-81 MAT. MEDICATION BUPREN+NALOX /SUBOXONE SUBLING
2026-07-09$795
Department of Justice
FY26 B1 MCKESSON MEDICATION JUL 26
2026-07-09$465
Department of Justice
MCKESSON MAT CONTROL MEDICATIONS CONTRACT # 36W79720D0001 CURRENT PERFORMANCE PERIOD 8-10-24 TO 8-9-26 ALL TERMS AND CONDITIONS REMAIN THE SAME UNDER PARENT CONTRACT SAM VERIFIED

Lobbying filings

all →

2026-04-20$860K
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors);S. 3822, Break Up Big Medicine Act; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex
2026-04-20$60K
MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY)
Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain; HR4299, Protecting Patient Access to Cancer and Complex Therapies Act. H.R.2484, Seniors Access to Critical Medications Act of 2025
2026-04-20$50K
MCKESSON CORPORATION
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
2026-04-20$50K
MCKESSON CORPORATION
Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency, 2026 rule and drug reimbursement changes.
2026-04-20$40K
MCKESSON SPECIALTY HEALTH
Radiation Oncology payment proposals in the CY 2026 Physician Fee Schedule proposed rule.
2026-04-20$30K
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases). H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Pr
2026-04-15$60K
MCKESSON CORPORATION
Issues related to the pharmaceutical supply chain and drug shortages. Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act. Issues related to pharmacies and patient access.
2026-02-13$0
MCKESSON CORPORATION
Issues around interoperability, data privacy and sharing in healthcare, drug shortages and healthcare transparency, 2026 rule and drug reimbursement changes.
2026-01-20$60K
MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY)
Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain. H.R.2484, Seniors Access to Critical Medications Act of 2025
2026-01-20$50K
MCKESSON CORPORATION
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.

Loading trade analytics…

All Disclosed Trades

Page 1 · 25 of 97 shown

Date	Member	Action	Amount	Observed Gap	Receipt
2026-07-08	DRick Larsen	BUY	$1K – $15K	5d	receipt →
2026-06-02	DRo Khanna	SELL	$1K – $15K	34d	receipt →
2026-05-27	DRo Khanna	BUY	$1K – $15K	13d	receipt →
2026-05-15	DRo Khanna	SELL	$15K – $50K	25d	receipt →
2026-05-01	DRo Khanna	SELL	$1K – $15K	39d	receipt →
2026-04-08	DLizzie Fletcher	SELL	$1K – $15K	23d	receipt →
2026-04-08	DLizzie Fletcher	SELL	$1K – $15K	23d	receipt →
2026-03-23	DRo Khanna	SELL	$1K – $15K	15d	receipt →
2026-03-23	DRo Khanna	SELL	$1K – $15K	15d	receipt →
2026-02-24	DRo Khanna	BUY	$1K – $15K	13d	receipt →
2026-02-24	DRo Khanna	BUY	$1K – $15K	13d	receipt →
2025-12-02	DJared Moskowitz	BUY	$1K – $15K	48dApparent delay	receipt →
2025-12-02	DJared Moskowitz	BUY	$1K – $15K	45d	receipt →
2025-12-02	DJared Moskowitz	BUY	$1K – $15K	45d	receipt →
2024-12-18	RJulia Letlow	BUY	$1K – $15K	391dApparent delay	receipt →
2024-12-18	RJulia Letlow	BUY	$1K – $15K	391dApparent delay	receipt →
2025-12-19	DGilbert Cisneros	SELL	$1K – $15K	25d	receipt →
2025-12-19	DGilbert Cisneros	SELL	$1K – $15K	24d	receipt →
2025-12-19	DGilbert Cisneros	SELL	$1K – $15K	24d	receipt →
2025-11-18	DGilbert Cisneros	BUY	$1K – $15K	28d	receipt →
2025-11-18	DGilbert Cisneros	BUY	$1K – $15K	27d	receipt →
2025-11-18	DGilbert Cisneros	BUY	$1K – $15K	27d	receipt →
2025-11-03	DRo Khanna	BUY	$1K – $15K	35d	receipt →
2025-11-03	DRo Khanna	BUY	$1K – $15K	35d	receipt →
2025-10-10	DJared Moskowitz	BUY	$1K – $15K	45d	receipt →

Load more trades →

“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.